Genelux (GNLX) Common Equity (2022 - 2026)
Genelux (GNLX) posted quarterly Common Equity of $22.9 million for Q1 2026, down 23.2% year-over-year from $29.8 million in Q1 2025, and up 98.55% quarter-over-quarter from $11.5 million in Q4 2025.
Genelux (GNLX) Common Equity (2022 - 2026) Analysis & Trends
Genelux's Common Equity history runs 5 years deep, the most recent figure standing at $22.9 million for Q1 2026.
- In Q1 2026, Common Equity fell 23.2% year-over-year to $22.9 million; the TTM figure through Mar 2026 stood at $22.9 million (down 23.2% YoY), while the FY2025 annual figure was $11.5 million, down 56.06% from the prior year.
- Common Equity for Q1 2026 stood at $22.9 million, up from $11.5 million in the prior quarter.
- The five-year high for Common Equity was $37.7 million in Q2 2024, with the low at -$35.8 million in Q4 2022.
- The 5-year median for Common Equity is $22.3 million (2023), against an average of $14.6 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity soared 460.54% in 2024, then slumped 56.06% in 2025.
- Genelux's Common Equity stood at -$35.8 million in 2022, then soared by 154.42% to $19.5 million in 2023, then soared by 34.93% to $26.3 million in 2024, then plunged by 56.06% to $11.5 million in 2025, then surged by 98.55% to $22.9 million in 2026.
- Business Quant data shows GNLX's Common Equity at $22.9 million in Q1 2026, $11.5 million in Q4 2025, and $18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | 22.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.92 Mn |
| Dec 31, 2025 | 11.54 Mn |
| Sep 30, 2025 | 18.59 Mn |
| Jun 30, 2025 | 23.90 Mn |
| Mar 31, 2025 | 29.85 Mn |
| Dec 31, 2024 | 26.27 Mn |
| Sep 30, 2024 | 33.09 Mn |
| Jun 30, 2024 | 37.67 Mn |
| Mar 31, 2024 | 15.08 Mn |
| Dec 31, 2023 | 19.47 Mn |
| Sep 30, 2023 | 24.03 Mn |
| Jun 30, 2023 | 22.26 Mn |
| Mar 31, 2023 | 2.69 Mn |
| Dec 31, 2022 | -35.78 Mn |
| Sep 30, 2022 | -32.33 Mn |